Thyroid News and Research

RSS
Dedicated palliative care consults improve outcomes

Dedicated palliative care consults improve outcomes

Patient-managed weight-loss program works

Patient-managed weight-loss program works

God will control my asthma

God will control my asthma

Graphic images best anti-smoking message

Graphic images best anti-smoking message

Radioactive iodine benefits selected papillary thyroid cancer patients

Radioactive iodine benefits selected papillary thyroid cancer patients

Hospice use driven by finance rather than patient eligibility

Hospice use driven by finance rather than patient eligibility

The argument for vision insurance

The argument for vision insurance

Telestroke networks benefit hospital bank balances

Telestroke networks benefit hospital bank balances

Meals on wheels reduces nursing home strain

Meals on wheels reduces nursing home strain

Genzyme receives EC approval for Thyrogen product label expansion

Genzyme receives EC approval for Thyrogen product label expansion

Pay for performance may have reduced UK mortality rates

Pay for performance may have reduced UK mortality rates

Protected sleep, shorter rotations may improve clinicians’ performance

Protected sleep, shorter rotations may improve clinicians’ performance

Obesity ramps up thoracic surgery costs

Obesity ramps up thoracic surgery costs

Resolving conflict over treatment decisions sometimes impossible

Resolving conflict over treatment decisions sometimes impossible

Websites offering 'designer vaginas' lack information

Websites offering 'designer vaginas' lack information

Elderly depression at discharge related to future outcomes

Elderly depression at discharge related to future outcomes

Phone, letter prompts improve statin uptake

Phone, letter prompts improve statin uptake

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.